Open Interest Spike and Volume Dynamics
On 31 August 2026, Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by 3,970 contracts, a 15.06% increase from the previous day’s 26,354 to 30,324. This notable rise in OI was accompanied by a robust volume of 46,614 contracts, indicating active participation from traders and investors. The futures segment alone accounted for a value of approximately ₹40,767 lakhs, while options contributed an overwhelming ₹40,208 crores in notional value, culminating in a total derivatives value of ₹49,303 lakhs.
This surge in open interest, combined with elevated volumes, often reflects fresh capital inflows and new positions being established rather than mere unwinding of existing trades. Such a pattern suggests that market participants are positioning themselves for a potential directional move in the stock.
Price Performance and Technical Strength
Aurobindo Pharma’s underlying share price closed at ₹1,684, just 0.39% shy of its 52-week high of ₹1,682.4, underscoring its strong price momentum. The stock has outperformed its sector by 2.41% on the day and has recorded a consecutive five-day gain, delivering a cumulative return of 4.22% over this period. Notably, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained bullish trend.
Despite this positive price action, delivery volumes have declined by 41.69% compared to the five-day average, with only 2.37 lakh shares delivered on 28 August. This divergence between rising derivatives activity and falling delivery volumes may indicate that short-term traders and institutional participants are driving the current momentum rather than retail investors holding shares for the long term.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Market Positioning and Potential Directional Bets
The sharp increase in open interest alongside rising volumes suggests that traders are actively building positions in anticipation of further upside. Given the stock’s proximity to its 52-week high and strong technical indicators, the market appears to be favouring bullish bets. The 15.06% jump in OI is a clear sign of fresh long positions being initiated rather than short covering, which typically results in a decline in open interest.
Moreover, the futures value of ₹40,767 lakhs and the substantial options notional value highlight the significant capital allocation towards Aurobindo Pharma derivatives. This level of activity often precedes notable price movements, as institutional players and hedge funds adjust their exposure based on evolving fundamentals and technical cues.
Fundamental Context and Mojo Rating Update
Aurobindo Pharma, a mid-cap player in the Pharmaceuticals & Biotechnology sector with a market capitalisation of ₹94,609 crores, recently saw its Mojo Grade downgraded from Buy to Hold on 25 May 2026. The current Mojo Score stands at 62.0, reflecting a cautious stance amid mixed signals from fundamentals and valuation metrics. While the stock has demonstrated resilience and outperformance in recent sessions, the downgrade suggests that investors should weigh the risks carefully before committing fresh capital.
Despite the Hold rating, the stock’s technical strength and rising derivatives interest indicate that momentum traders and short-term investors may find opportunities in the near term. The sector’s overall performance, however, remains subdued with the Pharmaceuticals & Biotechnology sector returning -0.47% on the day, contrasting with Aurobindo Pharma’s 2.17% gain and the Sensex’s 0.49% decline.
Aurobindo Pharma Ltd. or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Implications for Investors and Traders
The current surge in open interest and volume in Aurobindo Pharma’s derivatives market signals a growing conviction among traders about the stock’s near-term prospects. Investors should note the stock’s strong technical positioning, with prices comfortably above all major moving averages and near record highs. This technical backdrop supports the possibility of continued upward momentum.
However, the decline in delivery volumes and the Hold rating from MarketsMOJO suggest a degree of caution. Long-term investors may prefer to monitor fundamental developments and valuation metrics closely before increasing exposure. Meanwhile, short-term traders could capitalise on the heightened volatility and liquidity, especially given the stock’s ability to absorb sizeable trade sizes of around ₹2.28 crores based on recent average traded value.
Conclusion
Aurobindo Pharma Ltd. is currently experiencing a notable increase in derivatives open interest and trading volumes, reflecting active market positioning and bullish sentiment. The stock’s technical strength and proximity to 52-week highs reinforce the positive momentum, although fundamental caution remains warranted given the recent Mojo Grade downgrade. Market participants should balance these factors carefully, considering both the opportunities presented by the derivatives activity and the underlying sector dynamics.
As the pharmaceutical sector navigates evolving market conditions, Aurobindo Pharma’s derivatives surge offers a window into investor expectations and potential price trajectories in the coming sessions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
